Global End Stage Renal Disease Treatment Market Growth (Status and Outlook) 2023-2029

Global End Stage Renal Disease Treatment Market Growth (Status and Outlook) 2023-2029

End-stage renal failure, also known as end-stage renal disease (ESRD), is can be caused by an underlying health problem, often diabetes or high blood pressure. ESRD is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. When the kidneys can no longer filter the blood of waste and extra fluid, patients need dialysis or a kidney transplant to survive.

LPI (LP Information)' newest research report, the “End Stage Renal Disease Treatment Industry Forecast” looks at past sales and reviews total world End Stage Renal Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected End Stage Renal Disease Treatment sales for 2023 through 2029. With End Stage Renal Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world End Stage Renal Disease Treatment industry.

This Insight Report provides a comprehensive analysis of the global End Stage Renal Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on End Stage Renal Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global End Stage Renal Disease Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for End Stage Renal Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global End Stage Renal Disease Treatment.

The global End Stage Renal Disease Treatment market size is projected to grow from US$ 54130 million in 2022 to US$ 79600 million in 2029; it is expected to grow at a CAGR of 5.7% from 2023 to 2029.

Fresenius is one of the most important global key players of the end stage renal disease treatment, holds about 20% of shares of the global end stage renal disease treatment market, other key players include DaVita, Baxter, etc. North America is the largest market, occupied for about 40 percent, followed by the Asia Pacific. In terms of type, hemodialysis is the largest segment, with a share of about 70%, and in terms of application, the kidney dialysis centers segment holds a share of over 60 percent.

This report presents a comprehensive overview, market shares, and growth opportunities of End Stage Renal Disease Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Hemodialysis
Peritoneal Dialysis
Kidney Transplantation

Segmentation by application
Hospitals
Kidney Dialysis Centers
At Homes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Fresenius
DaVita
Baxter
Nipro
B. Braun
Asahi Kasei
Nikkiso
WEGO
Newsol
Mayo Clinic
Guangdong Biolight
Medtronic
Sanxin Medtec
Jafron Biomedical
SWS Hemodialysis Care
Tianyi Medical

Please note: The report will take approximately 2 business days to prepare and deliver.